

IS THERE A MITE PARTY ON YOUR EYELIDS?



Images are character representations of *Demodex* mites.

If you're experiencing red, irritated, crusty eyelids, it may be time to talk to your eye doctor.¹⁻³ **Demodex blepharitis**—also known as DB—is an eyelid disease caused by an infestation of *Demodex* mites, which are a common mite found on humans.^{1,2} **It's estimated that approximately 25 million mite parties are happening now.**^{3,4*}

*It's estimated that approximately 25 million eye care patients in the US are affected by DB.^{3,4}

PREPARING TO DISCUSS YOUR SYMPTOMS

It's important that your eye doctor is aware of the symptoms you are currently experiencing, so they can check to see if it may be due to DB. Fill out this checklist and bring it to your next appointment to have a more productive discussion.

**Complete this checklist
and take it to your next
eye doctor appointment.**

➔ Over the past month, which signs and symptoms have you experienced?¹⁻³

- | | |
|---|---|
| <input type="radio"/> Eyelid redness | <input type="radio"/> Misdirected eyelashes |
| <input type="radio"/> Crusties (collarettes) on eyelashes | <input type="radio"/> Inflammation |
| <input type="radio"/> Irritation | |

➔ How are you currently managing your symptoms?

- | | |
|---|---------------------------------------|
| <input type="radio"/> Eyelid cleanser | <input type="radio"/> Warm compresses |
| <input type="radio"/> Eyelid wipes | <input type="radio"/> Baby shampoo |
| <input type="radio"/> Eyelid foams | <input type="radio"/> Other _____ |
| <input type="radio"/> In-office treatment | |

➔ How would you describe your current symptom management plan?

- | | |
|--|--|
| <input type="radio"/> Cumbersome | <input type="radio"/> Working OK but could be better |
| <input type="radio"/> Difficult to adhere to | <input type="radio"/> Working OK |
| <input type="radio"/> Not managing my symptoms | <input type="radio"/> Other _____ |

➔ Have your symptoms made it harder to do any of these daily activities?

- | | |
|---|--------------------------------------|
| <input type="radio"/> School/office work | <input type="radio"/> Wearing makeup |
| <input type="radio"/> Family or social gatherings | <input type="radio"/> Other _____ |
| <input type="radio"/> Taking vacations or travel | |

Indications and Usage

XDEMVEY (lotilaner ophthalmic solution) 0.25% is indicated for the treatment of *Demodex* blepharitis.

Important Safety Information

Most common side effects: The most common side effect in clinical trials was stinging and burning in 10% of patients. Other side effects in less than 2% of patients were chalazion/hordeolum and punctate keratitis.

Please see additional Important Safety Information on page 2 and full Prescribing Information.

IF THERE'S A MITE PARTY ON YOUR EYELIDS, XDEMVMY® CAN HELP

xdemvy®
(lotilaner ophthalmic solution) 0.25%




Images are character representations of *Demodex* mites. One drop per eye, twice a day (~12 hours apart), for 6 weeks.

Your eye doctor can prescribe XDEMVMY, which was created specifically to treat DB. It is the **first and only FDA-approved eye drop treatment** that targets and kills the *Demodex* mites that cause *Demodex* blepharitis (DB).⁵

➔ ONE DROP PER EYE, TWICE A DAY, APPROXIMATELY 12 HOURS APART, IN JUST 6 WEEKS

In 2 combined studies, 50% of patients had a reduction of crusties (collarettes) and 60% of patients had their *Demodex* mites completely wiped out^{6*}



Patient with DB used XDEMVMY twice daily, in each eye, for 6 weeks. Results may vary.

➔ DESIGNED WITH YOUR COMFORT IN MIND

~90% of patients in both trials reported XDEMVMY eye drops as neutral to very comfortable to use^{6†}

➔ TARSUS CONNECT

Tarsus is committed to making XDEMVMY affordable and accessible. The majority of patients will pay as little as \$50[‡]



Need an eye doctor? Scan this QR code or visit [XDEMVMY.com](https://www.xdemvy.com) to find nearby eye doctors.

IF YOU HAVE DB, ASK YOUR EYE DOCTOR IF XDEMVMY CAN HELP.

*XDEMVMY for *Demodex* blepharitis was evaluated in 2 pivotal trials of 833 patients (415 received XDEMVMY).^{5,7,8}

Trial 1: When taken twice daily in each eye for 6 weeks, XDEMVMY reduced collarettes to 2 or fewer for the upper eyelid in 44% of patients (n=209) at Day 43; XDEMVMY eradicated mites (mite density of 0 mites/lash) in 68% of patients (n=212) at Day 43.

Trial 2: When taken twice daily in each eye for 6 weeks, XDEMVMY reduced collarettes to 2 or fewer for the upper eyelid in 55% of patients (n=193) at Day 43; XDEMVMY eradicated mites (mite density of 0 mites/lash) in 50% of patients (n=203) at Day 43.

†All visits averaged.⁶

‡With payer coverage and available assistance options, and based on eligibility requirements; see XDEMVMY Savings and Access Terms and Conditions.

Important Safety Information (Cont'd)

Handling the Container: Avoid allowing the tip of the dispensing container to contact the eye, surrounding structures, fingers, or any other surface in order to minimize contamination of the solution. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.

When to Seek Physician Advice: Immediately seek a physician's advice concerning the continued use of XDEMVMY if you develop an intercurrent ocular condition (e.g., trauma or infection), have ocular surgery, or develop any ocular reactions, particularly conjunctivitis and eyelid reactions.

Use with Contact Lenses: XDEMVMY contains potassium sorbate, which may discolor soft contact lenses. Contact lenses should be removed prior to instillation of XDEMVMY and may be reinserted 15 minutes following its administration.

To report SUSPECTED ADVERSE REACTIONS, contact Tarsus Pharmaceuticals at 1-888-421-4002 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full **Prescribing Information**.

References: 1. Fromstein SR, Harthan JS, Patel J, Opitz DL. *Demodex* blepharitis: clinical perspectives. *Clin Optom (Auckl)*. 2018;10:57-63. 2. Rhee MK, Yeu E, Barnett M, et al. *Demodex* blepharitis: a comprehensive review of the disease, current management, and emerging therapies. *Eye Contact Lens*. 2023;49(8):311-318. 3. Trattler W, Karpecki P, Rapoport Y, et al. The prevalence of *Demodex* blepharitis in US eye care clinic patients as determined by collarettes: a pathognomonic sign. *Clin Ophthalmol*. 2022;16:1153-1164. 4. O'Dell L, Dierker DS, Devries DK, et al. Psychosocial impact of *Demodex* blepharitis. *Clin Ophthalmol*. 2022;16:2979-2987. 5. XDEMVMY. Prescribing Information. Tarsus Pharmaceuticals Inc; 2023. 6. Yeu E, Mun J, Vollmer P, et al. Treatment of *Demodex* blepharitis with lotilaner ophthalmic solution (0.25%): combined analysis of two pivotal randomized, vehicle-controlled, multicenter trials. Presented at: ARVO 2023; April 25-27, 2023; New Orleans, Louisiana. 7. Gaddie IB, Donnenfeld ED, Karpecki P, et al. Lotilaner Ophthalmic Solution 0.25% for *Demodex* Blepharitis: Randomized, Vehicle-Controlled, Multicenter, Phase 3 Trial (Saturn-2) [published online ahead of print, 2023 Jun 5]. *Ophthalmology*. 2023;S0161-6420(23)00392-5. 8. Yeu E, Wirta DL, Karpecki P, Baba SN, Holdbrook M; Saturn I Study Group. Lotilaner Ophthalmic Solution, 0.25%, for the Treatment of *Demodex* Blepharitis: Results of a Prospective, Randomized, Vehicle-Controlled, Double-Masked, Pivotal Trial (Saturn-1). *Cornea*. 2023;42(4):435-443.



©2024 Tarsus Pharmaceuticals, Inc.
Tarsus, the Tarsus logo, XDEMVMY, the XDEMVMY logo, and certain other trademarks herein are trademarks of Tarsus Pharmaceuticals, Inc.
US--2400023 3/24